Cell-free DNA level as a prognostic biomarker for epithelial ovarian cancer
- PMID: 22843932
Cell-free DNA level as a prognostic biomarker for epithelial ovarian cancer
Abstract
Background: The use of cell-free DNA (cfDNA) as a non-invasive biomarker has been evaluated in many types of cancer. This study investigated the prognostic significance of cfDNA level for ovarian cancer.
Materials and methods: Preoperative sera of 36 patients with ovarian cancer and of 16 with benign tumors were analyzed using commercially available copy number assay kits to measure the cfDNA level of genes including beta-2-microglobulin (B2M), member RAS oncogene family (RAB25), claudin 4 (CLDN4) and ATP-binding cassette subfamily F member 2 (ABCF2). Cox regression analysis was used to calculate hazard ratios (HR) and 95% confidence intervals (CI).
Results: cfDNA level of these genes had no association with other prognostic factors of ovarian cancer. In particular, in patients with advanced stage disease, a low RAB25 level was an independent prognostic factor for disease-free survival (HR=18.2, 95% CI=2.0-170.0) and overall survival (HR=33.6, 95% CI=1.8-634.8).
Conclusion: Our findings suggest that the preoperative serum cfDNA level of RAB25 could be a useful biomarker predicting survival outcomes in patients with advanced ovarian cancer.
Similar articles
-
Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer.Oncol Rep. 2010 Feb;23(2):579-84. Oncol Rep. 2010. PMID: 20043124
-
Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.Cancer. 2004 Jun 1;100(11):2387-95. doi: 10.1002/cncr.20213. Cancer. 2004. PMID: 15160342
-
Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR.Ann N Y Acad Sci. 2006 Sep;1075:230-4. doi: 10.1196/annals.1368.031. Ann N Y Acad Sci. 2006. PMID: 17108216
-
Current clinical use of biomarkers for epithelial ovarian cancer.Curr Opin Oncol. 2010 Sep;22(5):492-7. doi: 10.1097/CCO.0b013e32833c3351. Curr Opin Oncol. 2010. PMID: 20613519 Review.
-
Biomarker discovery in epithelial ovarian cancer by genomic approaches.Adv Cancer Res. 2007;96:1-22. doi: 10.1016/S0065-230X(06)96001-1. Adv Cancer Res. 2007. PMID: 17161674 Review.
Cited by
-
Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).Int J Oncol. 2018 Oct;53(4):1395-1434. doi: 10.3892/ijo.2018.4516. Epub 2018 Aug 6. Int J Oncol. 2018. PMID: 30085333 Free PMC article. Review.
-
Advances and challenges in the use of liquid biopsy in gynaecological oncology.Heliyon. 2024 Oct 15;10(20):e39148. doi: 10.1016/j.heliyon.2024.e39148. eCollection 2024 Oct 30. Heliyon. 2024. PMID: 39492906 Free PMC article. Review.
-
Prediction of the treatment response in ovarian cancer: a ctDNA approach.J Ovarian Res. 2020 Oct 19;13(1):124. doi: 10.1186/s13048-020-00729-1. J Ovarian Res. 2020. PMID: 33076944 Free PMC article. Review.
-
The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis.Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211043784. doi: 10.1177/15330338211043784. Technol Cancer Res Treat. 2021. PMID: 34817271 Free PMC article.
-
The Role of Circulating Tumor DNA in Ovarian Cancer.Cancers (Basel). 2024 Sep 10;16(18):3117. doi: 10.3390/cancers16183117. Cancers (Basel). 2024. PMID: 39335089 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
